| Positron emission tomography and lymphoma therapy. | |
| | |
MedLine Citation:
|
PMID: 11694779 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
FDG-PET is both able to provide information of lymphomatous organ involvement not available by conventional imaging techniques (US, CT, MRI) and to give reliable data otherwise obtainable only by using invasive procedures. As a whole body-screening technique, PET reduces diagnostic requirements and potential complications. Nevertheless the conventional imaging techniques are essential for the exact localisation and correct interpretation of PET findings. A number of factors that may produce false-positive results have to be taken into consideration, including post-treatment inflammatory changes and the sensitivity of the method in the setting of minimal residual disease. Despite its potential of a screening method being performed prior to other imaging procedures, PET is not yet established as a routine element for the primary staging of Hodgkin's disease and non-Hodgkin's lymphoma. Its value for re-staging is less doubtful due to the frequency of stage migration and possible changes in therapy related to the use of PET. Detailed cost-effectiveness studies are needed to assess the economic implications of an expanded use of PET in lymphoma therapy. |
| | |
Authors:
|
W Golder |
Related Documents
:
|
19022059 - Chapter 7. molecular imaging of tumor vasculature. 20146589 - Role of pet/ct imaging in stereotactic body radiotherapy. 19890899 - Noninvasive imaging surrogate of angiogenesis in osteosarcoma. 8416579 - Cutaneous t-cell lymphoma: ct in evaluation and staging. 19638859 - Magnetic resonance imaging of endometrial carcinoma. 21061329 - Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-bod... 11551729 - Development of a 1.0 t mr microscope using a nd-fe-b permanent magnet. 12793309 - Magnetic resonance spectroscopy in pediatric neurology. 8259399 - Aortic cobwebs: an anatomic marker identifying the false lumen in aortic dissection--im... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Onkologie Volume: 24 ISSN: 0378-584X ISO Abbreviation: Onkologie Publication Date: 2001 Oct |
Date Detail:
|
Created Date: 2001-11-05 Completed Date: 2002-01-22 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7808556 Medline TA: Onkologie Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 496-8 Citation Subset: IM |
Copyright Information:
|
Copyright 2001 S. Karger GmbH, Freiburg |
Affiliation:
|
Klinikum Benjamin Franklin, Freie Universität Berlin, Germany. golder@cipmail.ukbf.fu-berlin.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Fluorodeoxyglucose F18
/
diagnostic use Follow-Up Studies Humans Lymphoma / pathology, radionuclide imaging*, therapy Neoplasm Staging Neoplasm, Residual / pathology, radionuclide imaging, therapy Tomography, Emission-Computed* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated...
Next Document: Cancer treatment in the elderly